Mazor Robotics Ltd. (NASDAQ:MZOR)‘s stock had its “hold” rating reiterated by equities research analysts at Barclays PLC in a note issued to investors on Wednesday. They presently have a $34.00 target price on the medical instruments supplier’s stock. Barclays PLC’s price objective would indicate a potential downside of 35.84% from the company’s current price.

Several other equities research analysts also recently weighed in on the company. Needham & Company LLC reaffirmed a “hold” rating on shares of Mazor Robotics in a research report on Wednesday, August 30th. Ladenburg Thalmann Financial Services set a $54.00 price target on Mazor Robotics and gave the stock a “buy” rating in a research report on Wednesday, August 30th. Finally, Zacks Investment Research raised Mazor Robotics from a “sell” rating to a “buy” rating and set a $41.00 price target on the stock in a research report on Tuesday, August 15th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and two have given a buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $37.67.

Shares of Mazor Robotics (NASDAQ MZOR) traded down 1.85% during mid-day trading on Wednesday, hitting $52.99. The company had a trading volume of 448,330 shares. The company has a 50-day moving average price of $46.56 and a 200-day moving average price of $39.03. The company’s market capitalization is $1.28 billion. Mazor Robotics has a 1-year low of $20.19 and a 1-year high of $55.66.

Mazor Robotics (NASDAQ:MZOR) last announced its quarterly earnings results on Tuesday, August 1st. The medical instruments supplier reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.09. The company had revenue of $15.46 million for the quarter, compared to the consensus estimate of $15.38 million. Mazor Robotics had a negative return on equity of 28.51% and a negative net margin of 37.66%. The firm’s revenue for the quarter was up 86.7% compared to the same quarter last year. During the same period last year, the firm earned ($0.09) EPS. On average, equities analysts anticipate that Mazor Robotics will post ($0.77) EPS for the current year.

TRADEMARK VIOLATION NOTICE: “Mazor Robotics’ (MZOR) Hold Rating Reiterated at Barclays PLC” was originally reported by American Banking News and is the property of of American Banking News. If you are accessing this news story on another domain, it was copied illegally and republished in violation of United States & international copyright legislation. The original version of this news story can be viewed at https://www.americanbankingnews.com/2017/10/11/mazor-robotics-mzor-hold-rating-reiterated-at-barclays-plc.html.

Large investors have recently bought and sold shares of the company. Credit Suisse AG grew its position in shares of Mazor Robotics by 66.5% during the 1st quarter. Credit Suisse AG now owns 330,000 shares of the medical instruments supplier’s stock valued at $9,824,000 after acquiring an additional 131,804 shares during the period. Oracle Investment Management Inc. grew its position in shares of Mazor Robotics by 13.0% during the 4th quarter. Oracle Investment Management Inc. now owns 2,816,635 shares of the medical instruments supplier’s stock valued at $28,617,000 after acquiring an additional 323,724 shares during the period. Private Advisor Group LLC acquired a new stake in shares of Mazor Robotics during the 2nd quarter valued at about $517,000. Biondo Investment Advisors LLC acquired a new stake in shares of Mazor Robotics during the 2nd quarter valued at about $675,000. Finally, Suffolk Capital Management LLC acquired a new stake in shares of Mazor Robotics during the 3rd quarter valued at about $1,654,000. Hedge funds and other institutional investors own 25.92% of the company’s stock.

Mazor Robotics Company Profile

Mazor Robotics Ltd is an Israel-based medical device company that develops and markets surgical guidance systems and complementary products. It develops computerized and imaging-based systems in the field of spine surgery. Its products include: Renaissance Surgical Guidance System, which enables surgeons to advance from freehand surgical procedures to guided procedures, as well as Food and Drug Administration (FDA)-cleared and European Conformity (CE)-marked Renaissance System, used in spine surgeries, whether open or minimally invasive, for a number of clinical indications.

Analyst Recommendations for Mazor Robotics (NASDAQ:MZOR)

Receive News & Ratings for Mazor Robotics Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mazor Robotics Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.